BVX
NEUTRALBiotechnology Firm Sees Major Shareholder Reduce Stake
Biotechnology firm BiVictriX Therapeutics sees a major shareholder reduce its stake, potentially impacting the share price in the short term.
BVX
0.00%
Market Cap
Volume
0
NaN% of avg
P/E Ratio
N/A
EPS (TTM)
N/A
Beta
N/A
Day Range
p - p
52 Week Range
N/AppN/Ap
p
No data available for this timeframe
BVX
BADBiVictriX Therapeutics to Delist from AIM, Become Private Company
Biotech company BiVictriX to delist from AIM, become private entity
BVX
GOODBiVictriX Reports Positive Preclinical Data for Solid Tumor Candidate BVX002
Biotech company BiVictriX reports positive preclinical data for its solid tumor candidate BVX002, showcasing the potential of its innovative cancer therapy platform.
BVX
GOODSpreadex Increases Stake in BiVictriX Therapeutics
Biotechnology company BiVictriX sees increased investment from major shareholder Spreadex
BVX
NEUTRALDirector Carries Out 'Bed and ISA' Transfer at BiVictriX Therapeutics
A biotech company announces a director's portfolio management transaction, unlikely to significantly impact the share price.
BVX
NEUTRALSpreadex Increases Stake in BiVictriX Therapeutics
Biotechnology company sees increased institutional investment, but faces challenges due to small size and limited analyst coverage.
BVX
GOODMajor Shareholder Increases Stake in BiVictriX Therapeutics
Biotech firm BiVictriX sees increased investor confidence as major shareholder boosts stake
BVX
NEUTRALInvestor Increases Stake in BiVictriX Therapeutics
Biotech company BiVictriX Therapeutics sees increase in major shareholder's stake.
BVX
NEUTRALBiVictriX Grants Options to Directors and PDMRs
Biotech company BiVictriX grants options to directors and key personnel, with a mix of positive and negative elements.
BVX
NEUTRALBiVictriX Therapeutics Proposes Voluntary Delisting from AIM
Biotech company proposing to delist from AIM to pursue greater funding as a private firm